Active Ingredient History
Istradefylline is a first-in-class adenosine A2A receptor antagonist antiparkinsonian agent and has been marketed as the brand name NOURIAST® in Japan since May 30, 2013. NOURIAST is indicated for the improvement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment with levodopa-containing products. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Parkinson Disease (approved 2013)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Cognitive Dysfunction (Phase 2)
Liver Diseases (Phase 1)
Movement Disorders (Phase 2)
Parkinson Disease (Phase 4)
Restless Legs Syndrome (Phase 2)
Sleep Wake Disorders (Phase 2)
Spinal Cord Diseases (Phase 1/Phase 2)
Spinal Cord Injuries (Phase 1/Phase 2)
Substance-Related Disorders (Phase 1)
Tremor (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue